Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium.
Identifieur interne : 000022 ( Main/Exploration ); précédent : 000021; suivant : 000023Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium.
Auteurs : Laetitia Gerlier [Belgique] ; Mark Lamotte [Belgique] ; Sofia Dos Santos Mendes [Belgique] ; Oliver Damm [Allemagne] ; Markus Schwehm [Allemagne] ; Martin Eichner [Allemagne]Source :
- Paediatric drugs [ 1179-2019 ] ; 2016.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins atténués.
- Administration par voie nasale, Adolescent, Belgique, Enfant, Enfant d'âge préscolaire, Grippe humaine, Humains, Programmes de vaccination, Risque, Santé publique, Vaccination.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Attenuated.
- methods : Immunization Programs, Vaccination.
- prevention & control : Influenza, Human.
- Administration, Intranasal, Adolescent, Belgium, Child, Child, Preschool, Humans, Public Health, Risk.
Abstract
OBJECTIVES
Our objectives were to estimate the public health outcomes of vaccinating Belgian children using an intranasal tetravalent live-attenuated influenza vaccine (QLAIV) combined with current coverage of high-risk/elderly individuals using the trivalent inactivated vaccine.
METHODS
We used a deterministic, age-structured, dynamic model to simulate seasonal influenza transmission in the Belgian population under the current coverage or after extending vaccination with QLAIV to healthy children aged 2-17 years. Differential equations describe demographic changes, exposure to infectious individuals, infection recovery, and immunity dynamics. The basic reproduction number (R 0) was calibrated to the observed number of influenza doctor visits/year. Vaccine efficacy was 80 % (live-attenuated) and 59-68 % (inactivated). The 10-year incidence of symptomatic influenza was calculated with different coverage scenarios (add-on to current coverage).
RESULTS
Model calibration yielded R 0 = 1.1. QLAIV coverage of 75 % of those aged 2-17 years averted 374,000 symptomatic cases/year (57 % of the current number), 244,000 of which were among adults (indirect effect). Vaccinating 75 % of those aged 2-11 years and 50 % of those aged 12-17 years averted 333,200 cases/year (213,000 adult cases/year). Vaccinating only healthy children aged 2-5 years generated direct protection but limited indirect protection, even with 90 % coverage (40,800 averted adult cases/year; -8.4 %). Targeting all children averted twice as many high-risk cases as targeting high-risk children only (8485 vs. 4965/year with 75 % coverage). Sensitivity analyses showed the robustness of results.
CONCLUSIONS
The model highlights the direct and indirect protection benefits when vaccinating healthy children with QLAIV in Belgium. Policies targeting only high-risk individuals or the youngest provide limited herd protection, as school-age children are important influenza vectors in the community.
DOI: 10.1007/s40272-016-0180-6
PubMed: 27272706
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium.</title><author><name sortKey="Gerlier, Laetitia" sort="Gerlier, Laetitia" uniqKey="Gerlier L" first="Laetitia" last="Gerlier">Laetitia Gerlier</name><affiliation wicri:level="1"><nlm:affiliation>IMS Health Real-World Evidence Solutions, Corporate Village, Davos Building, Da Vincilaan 7, 1935, Zaventem, Belgium. LGerlier@be.imshealth.com.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>IMS Health Real-World Evidence Solutions, Corporate Village, Davos Building, Da Vincilaan 7, 1935, Zaventem</wicri:regionArea><wicri:noRegion>Zaventem</wicri:noRegion></affiliation></author><author><name sortKey="Lamotte, Mark" sort="Lamotte, Mark" uniqKey="Lamotte M" first="Mark" last="Lamotte">Mark Lamotte</name><affiliation wicri:level="1"><nlm:affiliation>IMS Health Real-World Evidence Solutions, Corporate Village, Davos Building, Da Vincilaan 7, 1935, Zaventem, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>IMS Health Real-World Evidence Solutions, Corporate Village, Davos Building, Da Vincilaan 7, 1935, Zaventem</wicri:regionArea><wicri:noRegion>Zaventem</wicri:noRegion></affiliation></author><author><name sortKey="Dos Santos Mendes, Sofia" sort="Dos Santos Mendes, Sofia" uniqKey="Dos Santos Mendes S" first="Sofia" last="Dos Santos Mendes">Sofia Dos Santos Mendes</name><affiliation wicri:level="1"><nlm:affiliation>S.A. AstraZeneca N.V., Uccle, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>S.A. AstraZeneca N.V., Uccle</wicri:regionArea><wicri:noRegion>Uccle</wicri:noRegion></affiliation></author><author><name sortKey="Damm, Oliver" sort="Damm, Oliver" uniqKey="Damm O" first="Oliver" last="Damm">Oliver Damm</name><affiliation wicri:level="1"><nlm:affiliation>Bielefeld University, Bielefeld, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Bielefeld University, Bielefeld</wicri:regionArea><wicri:noRegion>Bielefeld</wicri:noRegion><wicri:noRegion>Bielefeld</wicri:noRegion><wicri:noRegion>Bielefeld</wicri:noRegion></affiliation></author><author><name sortKey="Schwehm, Markus" sort="Schwehm, Markus" uniqKey="Schwehm M" first="Markus" last="Schwehm">Markus Schwehm</name><affiliation wicri:level="1"><nlm:affiliation>ExploSYS GmbH, Leinfelden-Echterdingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>ExploSYS GmbH, Leinfelden-Echterdingen</wicri:regionArea><wicri:noRegion>Leinfelden-Echterdingen</wicri:noRegion><wicri:noRegion>Leinfelden-Echterdingen</wicri:noRegion><wicri:noRegion>Leinfelden-Echterdingen</wicri:noRegion></affiliation></author><author><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name><affiliation wicri:level="3"><nlm:affiliation>Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Tübingen</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Epimos GmbH, Dusslingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Epimos GmbH, Dusslingen</wicri:regionArea><wicri:noRegion>Dusslingen</wicri:noRegion><wicri:noRegion>Dusslingen</wicri:noRegion><wicri:noRegion>Dusslingen</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27272706</idno><idno type="pmid">27272706</idno><idno type="doi">10.1007/s40272-016-0180-6</idno><idno type="wicri:Area/Main/Corpus">000022</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000022</idno><idno type="wicri:Area/Main/Curation">000022</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000022</idno><idno type="wicri:Area/Main/Exploration">000022</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium.</title><author><name sortKey="Gerlier, Laetitia" sort="Gerlier, Laetitia" uniqKey="Gerlier L" first="Laetitia" last="Gerlier">Laetitia Gerlier</name><affiliation wicri:level="1"><nlm:affiliation>IMS Health Real-World Evidence Solutions, Corporate Village, Davos Building, Da Vincilaan 7, 1935, Zaventem, Belgium. LGerlier@be.imshealth.com.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>IMS Health Real-World Evidence Solutions, Corporate Village, Davos Building, Da Vincilaan 7, 1935, Zaventem</wicri:regionArea><wicri:noRegion>Zaventem</wicri:noRegion></affiliation></author><author><name sortKey="Lamotte, Mark" sort="Lamotte, Mark" uniqKey="Lamotte M" first="Mark" last="Lamotte">Mark Lamotte</name><affiliation wicri:level="1"><nlm:affiliation>IMS Health Real-World Evidence Solutions, Corporate Village, Davos Building, Da Vincilaan 7, 1935, Zaventem, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>IMS Health Real-World Evidence Solutions, Corporate Village, Davos Building, Da Vincilaan 7, 1935, Zaventem</wicri:regionArea><wicri:noRegion>Zaventem</wicri:noRegion></affiliation></author><author><name sortKey="Dos Santos Mendes, Sofia" sort="Dos Santos Mendes, Sofia" uniqKey="Dos Santos Mendes S" first="Sofia" last="Dos Santos Mendes">Sofia Dos Santos Mendes</name><affiliation wicri:level="1"><nlm:affiliation>S.A. AstraZeneca N.V., Uccle, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>S.A. AstraZeneca N.V., Uccle</wicri:regionArea><wicri:noRegion>Uccle</wicri:noRegion></affiliation></author><author><name sortKey="Damm, Oliver" sort="Damm, Oliver" uniqKey="Damm O" first="Oliver" last="Damm">Oliver Damm</name><affiliation wicri:level="1"><nlm:affiliation>Bielefeld University, Bielefeld, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Bielefeld University, Bielefeld</wicri:regionArea><wicri:noRegion>Bielefeld</wicri:noRegion><wicri:noRegion>Bielefeld</wicri:noRegion><wicri:noRegion>Bielefeld</wicri:noRegion></affiliation></author><author><name sortKey="Schwehm, Markus" sort="Schwehm, Markus" uniqKey="Schwehm M" first="Markus" last="Schwehm">Markus Schwehm</name><affiliation wicri:level="1"><nlm:affiliation>ExploSYS GmbH, Leinfelden-Echterdingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>ExploSYS GmbH, Leinfelden-Echterdingen</wicri:regionArea><wicri:noRegion>Leinfelden-Echterdingen</wicri:noRegion><wicri:noRegion>Leinfelden-Echterdingen</wicri:noRegion><wicri:noRegion>Leinfelden-Echterdingen</wicri:noRegion></affiliation></author><author><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name><affiliation wicri:level="3"><nlm:affiliation>Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Tübingen</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Epimos GmbH, Dusslingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Epimos GmbH, Dusslingen</wicri:regionArea><wicri:noRegion>Dusslingen</wicri:noRegion><wicri:noRegion>Dusslingen</wicri:noRegion><wicri:noRegion>Dusslingen</wicri:noRegion></affiliation></author></analytic><series><title level="j">Paediatric drugs</title><idno type="eISSN">1179-2019</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Adolescent</term><term>Belgium</term><term>Child</term><term>Child, Preschool</term><term>Humans</term><term>Immunization Programs (methods)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (prevention & control)</term><term>Public Health</term><term>Risk</term><term>Vaccination (methods)</term><term>Vaccines, Attenuated (administration & dosage)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term><term>Adolescent</term><term>Belgique</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Grippe humaine ()</term><term>Humains</term><term>Programmes de vaccination ()</term><term>Risque</term><term>Santé publique</term><term>Vaccination ()</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins atténués (administration et posologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization Programs</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Adolescent</term><term>Belgium</term><term>Child</term><term>Child, Preschool</term><term>Humans</term><term>Public Health</term><term>Risk</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Adolescent</term><term>Belgique</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Grippe humaine</term><term>Humains</term><term>Programmes de vaccination</term><term>Risque</term><term>Santé publique</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>Our objectives were to estimate the public health outcomes of vaccinating Belgian children using an intranasal tetravalent live-attenuated influenza vaccine (QLAIV) combined with current coverage of high-risk/elderly individuals using the trivalent inactivated vaccine.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We used a deterministic, age-structured, dynamic model to simulate seasonal influenza transmission in the Belgian population under the current coverage or after extending vaccination with QLAIV to healthy children aged 2-17 years. Differential equations describe demographic changes, exposure to infectious individuals, infection recovery, and immunity dynamics. The basic reproduction number (R 0) was calibrated to the observed number of influenza doctor visits/year. Vaccine efficacy was 80 % (live-attenuated) and 59-68 % (inactivated). The 10-year incidence of symptomatic influenza was calculated with different coverage scenarios (add-on to current coverage).</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Model calibration yielded R 0 = 1.1. QLAIV coverage of 75 % of those aged 2-17 years averted 374,000 symptomatic cases/year (57 % of the current number), 244,000 of which were among adults (indirect effect). Vaccinating 75 % of those aged 2-11 years and 50 % of those aged 12-17 years averted 333,200 cases/year (213,000 adult cases/year). Vaccinating only healthy children aged 2-5 years generated direct protection but limited indirect protection, even with 90 % coverage (40,800 averted adult cases/year; -8.4 %). Targeting all children averted twice as many high-risk cases as targeting high-risk children only (8485 vs. 4965/year with 75 % coverage). Sensitivity analyses showed the robustness of results.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The model highlights the direct and indirect protection benefits when vaccinating healthy children with QLAIV in Belgium. Policies targeting only high-risk individuals or the youngest provide limited herd protection, as school-age children are important influenza vectors in the community.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27272706</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-2019</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Paediatric drugs</Title><ISOAbbreviation>Paediatr Drugs</ISOAbbreviation></Journal><ArticleTitle>Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium.</ArticleTitle><Pagination><MedlinePgn>303-18</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40272-016-0180-6</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Our objectives were to estimate the public health outcomes of vaccinating Belgian children using an intranasal tetravalent live-attenuated influenza vaccine (QLAIV) combined with current coverage of high-risk/elderly individuals using the trivalent inactivated vaccine.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used a deterministic, age-structured, dynamic model to simulate seasonal influenza transmission in the Belgian population under the current coverage or after extending vaccination with QLAIV to healthy children aged 2-17 years. Differential equations describe demographic changes, exposure to infectious individuals, infection recovery, and immunity dynamics. The basic reproduction number (R 0) was calibrated to the observed number of influenza doctor visits/year. Vaccine efficacy was 80 % (live-attenuated) and 59-68 % (inactivated). The 10-year incidence of symptomatic influenza was calculated with different coverage scenarios (add-on to current coverage).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Model calibration yielded R 0 = 1.1. QLAIV coverage of 75 % of those aged 2-17 years averted 374,000 symptomatic cases/year (57 % of the current number), 244,000 of which were among adults (indirect effect). Vaccinating 75 % of those aged 2-11 years and 50 % of those aged 12-17 years averted 333,200 cases/year (213,000 adult cases/year). Vaccinating only healthy children aged 2-5 years generated direct protection but limited indirect protection, even with 90 % coverage (40,800 averted adult cases/year; -8.4 %). Targeting all children averted twice as many high-risk cases as targeting high-risk children only (8485 vs. 4965/year with 75 % coverage). Sensitivity analyses showed the robustness of results.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The model highlights the direct and indirect protection benefits when vaccinating healthy children with QLAIV in Belgium. Policies targeting only high-risk individuals or the youngest provide limited herd protection, as school-age children are important influenza vectors in the community.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gerlier</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IMS Health Real-World Evidence Solutions, Corporate Village, Davos Building, Da Vincilaan 7, 1935, Zaventem, Belgium. LGerlier@be.imshealth.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamotte</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IMS Health Real-World Evidence Solutions, Corporate Village, Davos Building, Da Vincilaan 7, 1935, Zaventem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos Mendes</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>S.A. AstraZeneca N.V., Uccle, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damm</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Bielefeld University, Bielefeld, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwehm</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ExploSYS GmbH, Leinfelden-Echterdingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichner</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epimos GmbH, Dusslingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Paediatr Drugs</MedlineTA><NlmUniqueID>100883685</NlmUniqueID><ISSNLinking>1174-5878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N">Belgium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="Y">Public Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27272706</ArticleId><ArticleId IdType="doi">10.1007/s40272-016-0180-6</ArticleId><ArticleId IdType="pii">10.1007/s40272-016-0180-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Glob Heart. 2014 Sep;9(3):325-36</Citation><ArticleIdList><ArticleId IdType="pubmed">25667184</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2011 Oct 13;365(15):1406-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21995388</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2013 Feb;131(2):207-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23296444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2013 Nov;132(5):796-804</Citation><ArticleIdList><ArticleId IdType="pubmed">24167165</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Health Econ. 2016 Jul;17 (6):669-79</Citation><ArticleIdList><ArticleId IdType="pubmed">26143025</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 2009 Oct;31(10):2140-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19922885</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2014 Jun;23(5):1651-60</Citation><ArticleIdList><ArticleId IdType="pubmed">24370954</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2014 Apr;33(4):569-75</Citation><ArticleIdList><ArticleId IdType="pubmed">24091746</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Mal Infect. 2009 Oct;39(10):780-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19796899</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2010 Dec 1;202(11):1626-33</Citation><ArticleIdList><ArticleId IdType="pubmed">21028955</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2012 Nov 12;12:968</Citation><ArticleIdList><ArticleId IdType="pubmed">23146107</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Sep 24;361(13):1260-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19776407</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2013 Jan 30;31(6):927-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23246550</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Jan 26;23(10):1284-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15652671</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2012 Sep-Oct;15(6):828-34</Citation><ArticleIdList><ArticleId IdType="pubmed">22999132</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2015;20(39):null</Citation><ArticleIdList><ArticleId IdType="pubmed">26537222</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Health Econ. 2015 Jun;16(5):471-88</Citation><ArticleIdList><ArticleId IdType="pubmed">24859492</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2001 Feb;20(2):127-33</Citation><ArticleIdList><ArticleId IdType="pubmed">11224828</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Jul 17;9(7):e102634</Citation><ArticleIdList><ArticleId IdType="pubmed">25032688</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Jan 15;33(4):535-41</Citation><ArticleIdList><ArticleId IdType="pubmed">25488331</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health Rep. 2014 May;129(3):229-36</Citation><ArticleIdList><ArticleId IdType="pubmed">24791020</ArticleId></ArticleIdList></Reference><Reference><Citation>Gac Sanit. 2009 Mar-Apr;23(2):104-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19442863</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Feb 1;30(6):1208-24</Citation><ArticleIdList><ArticleId IdType="pubmed">22178725</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Sep 16;29(40):7075-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21777639</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2014 Nov;17(7):A674</Citation><ArticleIdList><ArticleId IdType="pubmed">27202479</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr Health Care. 2011 May-Jun;25(3):171-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21514492</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(3):e60477</Citation><ArticleIdList><ArticleId IdType="pubmed">23555979</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2014 Jan 22;14:40</Citation><ArticleIdList><ArticleId IdType="pubmed">24450996</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2013 Sep;7 Suppl 2:76-81</Citation><ArticleIdList><ArticleId IdType="pubmed">24034489</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009 Oct 30;4(10):e7671</Citation><ArticleIdList><ArticleId IdType="pubmed">19876396</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(4):e60348</Citation><ArticleIdList><ArticleId IdType="pubmed">23565231</ArticleId></ArticleIdList></Reference><Reference><Citation>J Prim Prev. 2015 Aug;36(4):259-73</Citation><ArticleIdList><ArticleId IdType="pubmed">26032932</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2008 Apr 1;167(7):775-85</Citation><ArticleIdList><ArticleId IdType="pubmed">18230677</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2000 Nov;19(11):834-42</Citation><ArticleIdList><ArticleId IdType="pubmed">11152308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76</Citation><ArticleIdList><ArticleId IdType="pubmed">23210147</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Public Health. 2014 Sep 14;72(1):33</Citation><ArticleIdList><ArticleId IdType="pubmed">25705380</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Sep 26;26(41):5321-30</Citation><ArticleIdList><ArticleId IdType="pubmed">18647634</ArticleId></ArticleIdList></Reference><Reference><Citation>J Epidemiol Community Health. 1995 Aug;49(4):419-25</Citation><ArticleIdList><ArticleId IdType="pubmed">7650467</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2004 Oct 15;190(8):1369-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15378427</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Feb 11;27(7):1101-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19095024</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2007 Jul;26(7):619-28</Citation><ArticleIdList><ArticleId IdType="pubmed">17596805</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2010 Mar 10;303(10):943-50</Citation><ArticleIdList><ArticleId IdType="pubmed">20215608</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2008 Mar 25;5(3):e74</Citation><ArticleIdList><ArticleId IdType="pubmed">18366252</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2014 Jan 20;14:56</Citation><ArticleIdList><ArticleId IdType="pubmed">24443900</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2014 Jun 05;19(22):null</Citation><ArticleIdList><ArticleId IdType="pubmed">24925457</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2003 Feb 1;36(3):299-305</Citation><ArticleIdList><ArticleId IdType="pubmed">12539071</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2010 Sep;29(9):806-11</Citation><ArticleIdList><ArticleId IdType="pubmed">20458256</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2010 Feb 17;(2):CD004876</Citation><ArticleIdList><ArticleId IdType="pubmed">20166072</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004879</Citation><ArticleIdList><ArticleId IdType="pubmed">18425905</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Infect. 2014 Oct;142(10):2024-35</Citation><ArticleIdList><ArticleId IdType="pubmed">24480146</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Jan 1;33(1):246-51</Citation><ArticleIdList><ArticleId IdType="pubmed">24962752</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2013 Oct;10(10):e1001527</Citation><ArticleIdList><ArticleId IdType="pubmed">24115913</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2015 Jun 21;15:578</Citation><ArticleIdList><ArticleId IdType="pubmed">26093501</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Pediatr Adolesc Med. 2011 Feb;165(2):112-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20921341</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Belgique</li></country><region><li>Bade-Wurtemberg</li><li>District de Tübingen</li></region><settlement><li>Tübingen</li></settlement></list><tree><country name="Belgique"><noRegion><name sortKey="Gerlier, Laetitia" sort="Gerlier, Laetitia" uniqKey="Gerlier L" first="Laetitia" last="Gerlier">Laetitia Gerlier</name></noRegion><name sortKey="Dos Santos Mendes, Sofia" sort="Dos Santos Mendes, Sofia" uniqKey="Dos Santos Mendes S" first="Sofia" last="Dos Santos Mendes">Sofia Dos Santos Mendes</name><name sortKey="Lamotte, Mark" sort="Lamotte, Mark" uniqKey="Lamotte M" first="Mark" last="Lamotte">Mark Lamotte</name></country><country name="Allemagne"><noRegion><name sortKey="Damm, Oliver" sort="Damm, Oliver" uniqKey="Damm O" first="Oliver" last="Damm">Oliver Damm</name></noRegion><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name><name sortKey="Schwehm, Markus" sort="Schwehm, Markus" uniqKey="Schwehm M" first="Markus" last="Schwehm">Markus Schwehm</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeBelgiqueV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000022 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000022 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeBelgiqueV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27272706
|texte= Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27272706" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeBelgiqueV4
| This area was generated with Dilib version V0.6.35. |  |